2.77
+0(+0.00%)
Currency In USD
| Previous Close | 2.77 |
| Open | 2.75 |
| Day High | 2.9 |
| Day Low | 2.71 |
| 52-Week High | 6.15 |
| 52-Week Low | 1.63 |
| Volume | 84,657 |
| Average Volume | 79,073 |
| Market Cap | 14.11M |
| PE | -0.96 |
| EPS | -2.9 |
| Moving Average 50 Days | 2.41 |
| Moving Average 200 Days | 2.47 |
| Change | 0 |
If you invested $1000 in BioCardia, Inc. (BCDA) 10 years ago, it would be worth $5.67 as of May 15, 2025 at a share price of $2.77. Whereas If you bought $1000 worth of BioCardia, Inc. (BCDA) shares 5 years ago, it would be worth $13.9 as of May 15, 2025 at a share price of $2.77.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025
GlobeNewswire Inc.
May 09, 2025 8:28 PM GMT
SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update
BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study
GlobeNewswire Inc.
May 06, 2025 12:00 PM GMT
CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) and Elevated Markers of Cardiac Stress Dr. Amish Raval, Professor of Medicine at the University of
BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure
GlobeNewswire Inc.
May 01, 2025 1:00 PM GMT
SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the first patient enrolled in